Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset. The purpose of this study is to compare the effectiveness of ddI EC versus the standard form of ddI. Both forms of ddI will be given with stavudine (d4T) plus nelfinavir (NLF).
Patients are randomized to 1 of 2 open-label treatment groups. Group 1 receives ddI EC plus d4T plus NLF for 48 weeks. Group 2 receives ddI plus d4T plus NLF for 48 weeks. Both forms of ddI are administered orally once daily. Antiviral activity is determined by the magnitude and the duration of reduction of plasma HIV RNA from baseline through Week 24.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Sorra Research Ctr / Med Forum
Birmingham, Alabama, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
AIDS Healthcare Foundation
Los Angeles, California, United States
Robert Scott MD
Oakland, California, United States
Beacon Clinic / Boulder Community Hosp
Boulder, Colorado, United States
Community Health Care
Fort Lauderdale, Florida, United States
Immunity Care and Research Inc
Fort Lauderdale, Florida, United States
HIV Clinical Research Ctr
Fort Lauderdale, Florida, United States
South Shore Hosp
Miami, Florida, United States
Saint Josephs Comprehensive Research Institute
Tampa, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
...and 14 more locations